Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 (intravenous tolvaptan) in congestive heart failure patients unable to take oral medication
jRCT2080224643Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in heart failure (HF), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Tolerability at starting dose (8 mg) and after optional dose increase to 16 mg. Started Apr 2019; status: completed.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT2080224643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224643.